Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM159PT | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.000171 | uM | 10520.14 | 0.9190 | 0.9549 | 3.7031 | |
| SUM159PT | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.000853 | uM | 10520.14 | 0.9227 | 0.9570 | 3.7031 | |
| SUM159PT | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.00427 | uM | 10520.14 | 0.9018 | 0.9449 | 3.7031 | |
| SUM159PT | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.0213 | uM | 10520.14 | 1.0092 | 1.0049 | 3.7031 | |
| SUM159PT | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.107 | uM | 10520.14 | 0.9037 | 0.9461 | 3.7031 | |
| SUM159PT | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 0.533 | uM | 10520.14 | 0.8361 | 0.9056 | 3.7031 | |
| SUM159PT | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 2.67 | uM | 10520.14 | 0.8531 | 0.9160 | 3.7031 | |
| SUM159PT | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 13.3 | uM | 10520.14 | 0.8723 | 0.9276 | 3.7031 | |
| SUM159PT | TNBC | Basal B | Chk2 inhibitor II | CHK2 | CHK | 66.7 | uM | 10520.14 | 0.8478 | 0.9128 | 3.7031 | |
| SUM225CWN | HER2amp | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.000171 | uM | 10579.14 | 0.9879 | 0.9741 | 0.9303 | |
| SUM225CWN | HER2amp | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.000853 | uM | 10579.14 | 1.0427 | 1.0920 | 0.9303 | |
| SUM225CWN | HER2amp | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.00427 | uM | 10579.14 | 0.9233 | 0.8355 | 0.9303 | |
| SUM225CWN | HER2amp | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.0213 | uM | 10579.14 | 0.9769 | 0.9504 | 0.9303 | |
| SUM225CWN | HER2amp | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.107 | uM | 10579.14 | 1.0821 | 1.1771 | 0.9303 | |
| SUM225CWN | HER2amp | Basal A | Chk2 inhibitor II | CHK2 | CHK | 0.533 | uM | 10579.14 | 0.9876 | 0.9734 | 0.9303 | |
| SUM225CWN | HER2amp | Basal A | Chk2 inhibitor II | CHK2 | CHK | 2.67 | uM | 10579.14 | 0.9529 | 0.8989 | 0.9303 | |
| SUM225CWN | HER2amp | Basal A | Chk2 inhibitor II | CHK2 | CHK | 13.3 | uM | 10579.14 | 0.8495 | 0.6784 | 0.9303 | |
| SUM225CWN | HER2amp | Basal A | Chk2 inhibitor II | CHK2 | CHK | 66.7 | uM | 10579.14 | 0.9834 | 0.9644 | 0.9303 | |
| UACC-812 | HER2amp | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.000171 | uM | 10580.14 | 0.9505 | 0.8863 | 0.8679 | |
| UACC-812 | HER2amp | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.000853 | uM | 10580.14 | 0.9312 | 0.8422 | 0.8679 | |
| UACC-812 | HER2amp | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.00427 | uM | 10580.14 | 0.9286 | 0.8363 | 0.8679 | |
| UACC-812 | HER2amp | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.0213 | uM | 10580.14 | 0.9321 | 0.8444 | 0.8679 | |
| UACC-812 | HER2amp | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.107 | uM | 10580.14 | 0.9634 | 0.9158 | 0.8679 | |
| UACC-812 | HER2amp | Luminal | Chk2 inhibitor II | CHK2 | CHK | 0.533 | uM | 10580.14 | 0.9370 | 0.8556 | 0.8679 | |
| UACC-812 | HER2amp | Luminal | Chk2 inhibitor II | CHK2 | CHK | 2.67 | uM | 10580.14 | 0.9625 | 0.9139 | 0.8679 |